Four life sciences companies will see £277 million in joint government and industry backing to help grow and innovate. The funding forms the first tranche of winning grants from the Life Sciences Innovative Manufacturing Fund (LSIMF). The four companies are:
Ipsen - £75 million investment to grow the manufacture of innovative medicines for neurological conditions at their Wrexham facility
Pharmaron - £151 million investment in capital and people for operations in Liverpool, increasing production capacity four-fold for critical gene therapy and vaccine components.
Touchlight – £14 million investment establishing the commercial scale manufacture of DNA at their Hampton, London base
Randox - £36 million investment to modernise the manufacture of antibodies used across diagnostic tests in Crumlin, Northern Ireland.